KING OF PRUSSIA, Pa., Dec. 10, 2022 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced the presentation of data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb) in the treatment of certain adults living with hemophilia B at the 64th American Society of Hematology (ASH) Annual Meeting. Results from the pivotal HOPE-B study, the largest gene therapy study in hemophilia B to date, demonstrated that after two years of follow-up, adults with severe or moderately severe hemophilia B treated with a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX activity levels and durable hemostatic protection.
Read more at prnewswire.comCSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
